PMA device
Zenflow Spring® Implant and Delivery System
Zenflow, Inc. · Stent, Urethral, Prostatic, Permanent Or Semi-Permanent (MER, Class III) · First FDA decision Dec 11, 2025, newest Dec 11, 2025Enlarged prostate (BPH)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
7
Naming "Zenflow Spring"
MAUDE reports
0
Brand "Zenflow Spring", since 2015
PubMed studies
0
Mentioning "Zenflow Spring"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Zenflow Spring® Implant and Delivery System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P250007 · Decided Dec 11, 2025 · 275 days after receipt
Device type: STENT, URETHRAL, PROSTATIC, PERMANENT OR SEMI-PERMANENT (MER) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Zenflow Spring", any status and sponsor, newest update first.
- Prospective Post Market Clinical Trial for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH.Pivotal-lookingNot yet recruiting
Zenflow, Inc.Not on our public-company list
NCT07797348 · 110 participants (planned) · Start Sep 1, 2026 · Primary completion Sep 1, 2028
Device: Zenflow Arm: Zenflow Spring System implant procedure · For: Benign Prostatic Hyperplasia (BPH); Obstructive Lower Urinary Tract Symptoms (LUTS); Enlarged Prostate
Zenflow, Inc.Not on our public-company list
NCT07538622 · 300 participants (planned) · Start Jul 29, 2026 · Primary completion Jul 2028
Device: Zenflow Spring System · For: BPH (Benign Prostatic Hyperplasia)
Sites: Phoenix, Arizona; La Mesa, California; Tampa, Florida · 8 sites in all
- Safety and Effectiveness Study of the Zenflow Spring SystemPivotal-lookingStatus unknown
Zenflow, Inc.Not on our public-company list
NCT04987138 · 279 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2024
Device: Zenflow Spring System; Sham Procedure · For: BPH (Benign Prostatic Hyperplasia); Lower Urinary Tract Symptoms (LUTS)
Sites: Los Angeles, California; Glenview, Illinois; Las Vegas, Nevada · 7 sites in all
4 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Zenflow Spring", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MER
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Zenflow Spring"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MER.
- ProVee System for BPHProverum, Ltd. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.